Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
KYMR Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 05, 2026
Report Source: 2026 1st Quarter Report
Kymera Therapeutics Inc. Stock Analysis KYMR
United States Health Care Mid Cap Report: Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. The company is headquartered in Watertown, Massachusetts and currently employs 253 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.
Read More Kymera Therapeutics Inc (KYMR) Chart
Key Statistics of Kymera Therapeutics Inc (KYMR)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$97.77Volume
1.37MP/E Ratio (TTM)
-52 Week Range
Market Cap
6.63BAvg. Volume
796.44KDividend Yield
-Financial Metrics & Statements of Kymera Therapeutics Inc (KYMR)
FAQ's for Kymera Therapeutics Inc (KYMR)
- According to Musaffa’s Shariah screening methodology, Kymera Therapeutics Inc (KYMR) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kymera Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kymera Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kymera Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kymera Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kymera Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.